April 2 (Reuters) - Esperion Therapeutics Inc ESPR.O:
ATHYRIUM CAPITAL MANAGEMENT AND ESPERION ENTER INTO $50 MILLION JAPAN ROYALTY FINANCING TO SUPPORT STRATEGIC ACQUISITION OF CORSTASIS THERAPEUTICS
ESPERION THERAPEUTICS INC - ATHYRIUM FUNDS TO RECEIVE TIERED ROYALTIES OF 12%-33% AND MILESTONE PAYMENTS UNTIL 2.0X INVESTMENT
ESPERION THERAPEUTICS INC - FINANCING SUPPORTS ESPERION'S ACQUISITION OF CORSTASIS THERAPEUTICS, DEVELOPER OF ENBUMYST
ESPERION THERAPEUTICS INC - ATHYRIUM FUNDS TO BUY 100% OF ESPERION'S ROYALTY INTEREST ON OTSUKA'S JAPAN SALES FROM JAN 1, 2026